Safety and Efficacy of AIN457 in Noninfectious Uveitis
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT00685399
- Locations
- 🇩🇪
Novartis Investigative Site, Tübingen, Germany
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Phase 3
Completed
- Conditions
- Neoplasms, Gastrointestinal Tract
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 545
- Registration Number
- NCT00680901
- Locations
- 🇺🇦
Novartis Investigative Site, Zaporizhzhia, Ukraine
An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT00674102
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 111
- Registration Number
- NCT00670592
- Locations
- 🇺🇸
Dana Farber Cancer Institute SC-5, Boston, Massachusetts, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3), Houston, Texas, United States
Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
Phase 4
Completed
- Conditions
- Allergic Asthma
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT00670930
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer
Phase 1
Completed
- Conditions
- Head & Neck CancerProstate CancerEsophageal Cancer
- Interventions
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT00670553
- Locations
- 🇧🇪
Novartis Investigative Site, Liege, Belgium
Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: PlaceboBiological: AIN457
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT00669942
- Locations
- 🇪🇸
Novartis Investigative Site, Guadalajara, Spain
A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis
Phase 1
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: PlaceboBiological: AIN457
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT00669916
Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT00669097
- Locations
- 🇳🇱
Novartis Investigative Site, Amsterdam, Netherlands
Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®
Phase 4
Completed
- Conditions
- Paget's Disease of the BoneHypocalcemia
- Interventions
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 81
- Registration Number
- NCT00668200
- Locations
- 🇺🇸
Novartis Investigative Site, Madison, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath